Serum levels of 14‑3‑3η are associated with increased disease risk, activity and duration of rheumatoid arthritis in Chinese patients
The aim of the present study was to determine the association between serum 14-3-3η expression levels and disease risk, inflammation level and disease duration in Chinese patients with rheumatoid arthritis (RA). A total of 45 Chinese patients with RA, 45 patients with osteoarthritis (OA) and 44 age-...
Saved in:
Published in | Experimental and therapeutic medicine Vol. 20; no. 2; pp. 754 - 761 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Athens
Spandidos Publications UK Ltd
01.08.2020
D.A. Spandidos |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | The aim of the present study was to determine the association between serum 14-3-3η expression levels and disease risk, inflammation level and disease duration in Chinese patients with rheumatoid arthritis (RA). A total of 45 Chinese patients with RA, 45 patients with osteoarthritis (OA) and 44 age- and sex-matched (with the RA group) healthy control (HC) subjects were consecutively recruited for the present case-controlled study. In addition, the demographic and clinicopathological characteristics of the patients with RA were collected. Serum samples were obtained from patients with RA, patients with OA and the HCs, and the serum levels of 14-3-3η were determined by ELISA. Compared with that in the OA patients (P=0.006) and HCs (P<0.001), 14-3-3η expression was significantly increased in RA patients, and receiver operating characteristics (ROC) analysis indicated that it served as a potential predictive marker for the risk of RA. In patients with RA, serum levels of 14-3-3η were positively correlated with disease duration (P=0.003), erythrocyte sedimentation rate (P=0.006) and disease activity score in 28 joints (P=0.025). The proportion of rheumatoid factor (RF)-positive patients (P=0.023) and anti-citrullinated protein antibody (ACPA)-positive patients (P=0.002) with RA was increased (when 14-3-3η expression was increased) compared with RF-negative patients or ACPA-negative patients, respectively. Of note, 14-3-3η serum levels were able to distinguish patients with established RA (disease duration, >2 years) from patients with early RA (disease duration, ≤2 years) with an AUC of 0.759 (95% CI, 0.612-0.905), and the sensitivity and the specificity at the best cut-off point (14-3-3η=0.613 ng/ml) were 79.3 and 75.0%, respectively. Furthermore, 14-3-3η was able to differentiate between RF-positive RA patients and RF-negative patients or HCs. In conclusion, circulating 14-3-3η expression may serve as a novel biomarker for disease risk and activity of RA in Chinese patients. |
---|---|
AbstractList | The aim of the present study was to determine the association between serum 14-3-3η expression levels and disease risk, inflammation level and disease duration in Chinese patients with rheumatoid arthritis (RA). A total of 45 Chinese patients with RA, 45 patients with osteoarthritis (OA) and 44 age- and sex-matched (with the RA group) healthy control (HC) subjects were consecutively recruited for the present case-controlled study. In addition, the demographic and clinicopathological characteristics of the patients with RA were collected. Serum samples were obtained from patients with RA, patients with OA and the HCs, and the serum levels of 14-3-3η were determined by ELISA. Compared with that in the OA patients (P=0.006) and HCs (P<0.001), 14-3-3η expression was significantly increased in RA patients, and receiver operating characteristics (ROC) analysis indicated that it served as a potential predictive marker for the risk of RA. In patients with RA, serum levels of 14-3-3η were positively correlated with disease duration (P=0.003), erythrocyte sedimentation rate (P=0.006) and disease activity score in 28 joints (P=0.025). The proportion of rheumatoid factor (RF)-positive patients (P=0.023) and anti-citrullinated protein antibody (ACPA)-positive patients (P=0.002) with RA was increased (when 14-3-3η expression was increased) compared with RF-negative patients or ACPA-negative patients, respectively. Of note, 14-3-3η serum levels were able to distinguish patients with established RA (disease duration, >2 years) from patients with early RA (disease duration, ≤2 years) with an AUC of 0.759 (95% CI, 0.612-0.905), and the sensitivity and the specificity at the best cut-off point (14-3-3η=0.613 ng/ml) were 79.3 and 75.0%, respectively. Furthermore, 14-3-3η was able to differentiate between RF-positive RA patients and RF-negative patients or HCs. In conclusion, circulating 14-3-3η expression may serve as a novel biomarker for disease risk and activity of RA in Chinese patients.The aim of the present study was to determine the association between serum 14-3-3η expression levels and disease risk, inflammation level and disease duration in Chinese patients with rheumatoid arthritis (RA). A total of 45 Chinese patients with RA, 45 patients with osteoarthritis (OA) and 44 age- and sex-matched (with the RA group) healthy control (HC) subjects were consecutively recruited for the present case-controlled study. In addition, the demographic and clinicopathological characteristics of the patients with RA were collected. Serum samples were obtained from patients with RA, patients with OA and the HCs, and the serum levels of 14-3-3η were determined by ELISA. Compared with that in the OA patients (P=0.006) and HCs (P<0.001), 14-3-3η expression was significantly increased in RA patients, and receiver operating characteristics (ROC) analysis indicated that it served as a potential predictive marker for the risk of RA. In patients with RA, serum levels of 14-3-3η were positively correlated with disease duration (P=0.003), erythrocyte sedimentation rate (P=0.006) and disease activity score in 28 joints (P=0.025). The proportion of rheumatoid factor (RF)-positive patients (P=0.023) and anti-citrullinated protein antibody (ACPA)-positive patients (P=0.002) with RA was increased (when 14-3-3η expression was increased) compared with RF-negative patients or ACPA-negative patients, respectively. Of note, 14-3-3η serum levels were able to distinguish patients with established RA (disease duration, >2 years) from patients with early RA (disease duration, ≤2 years) with an AUC of 0.759 (95% CI, 0.612-0.905), and the sensitivity and the specificity at the best cut-off point (14-3-3η=0.613 ng/ml) were 79.3 and 75.0%, respectively. Furthermore, 14-3-3η was able to differentiate between RF-positive RA patients and RF-negative patients or HCs. In conclusion, circulating 14-3-3η expression may serve as a novel biomarker for disease risk and activity of RA in Chinese patients. The aim of the present study was to determine the association between serum 14-3-3η expression levels and disease risk, inflammation level and disease duration in Chinese patients with rheumatoid arthritis (RA). A total of 45 Chinese patients with RA, 45 patients with osteoarthritis (OA) and 44 age- and sex-matched (with the RA group) healthy control (HC) subjects were consecutively recruited for the present case-controlled study. In addition, the demographic and clinicopathological characteristics of the patients with RA were collected. Serum samples were obtained from patients with RA, patients with OA and the HCs, and the serum levels of 14-3-3η were determined by ELISA. Compared with that in the OA patients (P=0.006) and HCs (P<0.001), 14-3-3η expression was significantly increased in RA patients, and receiver operating characteristics (ROC) analysis indicated that it served as a potential predictive marker for the risk of RA. In patients with RA, serum levels of 14-3-3η were positively correlated with disease duration (P=0.003), erythrocyte sedimentation rate (P=0.006) and disease activity score in 28 joints (P=0.025). The proportion of rheumatoid factor (RF)-positive patients (P=0.023) and anti-citrullinated protein antibody (ACPA)-positive patients (P=0.002) with RA was increased (when 14-3-3η expression was increased) compared with RF-negative patients or ACPA-negative patients, respectively. Of note, 14-3-3η serum levels were able to distinguish patients with established RA (disease duration, >2 years) from patients with early RA (disease duration, ≤2 years) with an AUC of 0.759 (95% CI, 0.612-0.905), and the sensitivity and the specificity at the best cut-off point (14-3-3η=0.613 ng/ml) were 79.3 and 75.0%, respectively. Furthermore, 14-3-3η was able to differentiate between RF-positive RA patients and RF-negative patients or HCs. In conclusion, circulating 14-3-3η expression may serve as a novel biomarker for disease risk and activity of RA in Chinese patients. |
Author | Dai, Meijie Zhou, Yan Pan, Axiao Xia, Xiaoru Sun, Li Tu, Jianxin Chen, Xiaowei Liu, Cailong |
AuthorAffiliation | 3 Department of Orthopaedic Sports Medicine, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, P.R. China 1 Department of Rheumatology and Immunology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, P.R. China 2 Department of Laboratory Medicine, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, P.R. China |
AuthorAffiliation_xml | – name: 1 Department of Rheumatology and Immunology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, P.R. China – name: 3 Department of Orthopaedic Sports Medicine, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, P.R. China – name: 2 Department of Laboratory Medicine, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, P.R. China |
Author_xml | – sequence: 1 givenname: Jianxin surname: Tu fullname: Tu, Jianxin organization: Department of Rheumatology and Immunology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, P.R. China – sequence: 2 givenname: Xiaowei surname: Chen fullname: Chen, Xiaowei organization: Department of Rheumatology and Immunology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, P.R. China – sequence: 3 givenname: Meijie surname: Dai fullname: Dai, Meijie organization: Department of Laboratory Medicine, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, P.R. China – sequence: 4 givenname: Axiao surname: Pan fullname: Pan, Axiao organization: Department of Rheumatology and Immunology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, P.R. China – sequence: 5 givenname: Cailong surname: Liu fullname: Liu, Cailong organization: Department of Orthopaedic Sports Medicine, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, P.R. China – sequence: 6 givenname: Yan surname: Zhou fullname: Zhou, Yan organization: Department of Rheumatology and Immunology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, P.R. China – sequence: 7 givenname: Xiaoru surname: Xia fullname: Xia, Xiaoru organization: Department of Rheumatology and Immunology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, P.R. China – sequence: 8 givenname: Li surname: Sun fullname: Sun, Li organization: Department of Rheumatology and Immunology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000, P.R. China |
BookMark | eNptUb2O1DAQttAh7liupLdEQ8Eu_klip0FCK_6kkyiA2nKcWTJHYi-2s6frqOl4Gt6Ch-BJcO6WghOWLM9ovh-Nv4fkxAcPhDzmbCN1K55DnjaCCbbRquH3yBlXrVhzxuuTY81azU_JeUqXrJy64VrXD8ipFKoSUvAz8v0DxHmiIxxgTDTsKK9-f_shl_vrJ7URqE0pOLQZenqFeaDoXQSbSttjWgoaMX15Rq3LeMB8Ta0voznajMEvinGAebI5YF_08hAxYyoqdDugh0LfFyT4nB6R-zs7Jjg_vivy6fWrj9u364v3b95tX16snRQirzUXWklQPWNV1zktQUjrpNUdAKsFq1jLukY0jVZ1z5Xume7qdtfzFlSnGJcr8uJWdz93E_SueEc7mn3EycZrEyyafyceB_M5HIySWsvivSJPjwIxfJ0hZTNhcjCO1kOYkxGVZKytlKoL9Mkd6GWYoy_r3aAa1tRFc0XkLcrFkFKEnXGYb_6v-ONoODNL3KbEbZa4zRJ3Ya3vsP6u8H_8H0tFsOY |
CitedBy_id | crossref_primary_10_3892_etm_2023_12364 crossref_primary_10_5114_reum_2022_123669 crossref_primary_10_1515_rir_2024_0030 crossref_primary_10_1080_00325481_2022_2052626 crossref_primary_10_1016_j_ejr_2024_11_002 crossref_primary_10_2478_rir_2021_0012 |
ContentType | Journal Article |
Copyright | Copyright Spandidos Publications UK Ltd. 2020 Copyright: © Tu et al. Copyright: © Tu et al. 2020 |
Copyright_xml | – notice: Copyright Spandidos Publications UK Ltd. 2020 – notice: Copyright: © Tu et al. – notice: Copyright: © Tu et al. 2020 |
DBID | AAYXX CITATION 3V. 7RV 7X7 7XB 8FI 8FJ 8FK ABUWG AFKRA AN0 BENPR CCPQU FYUFA GHDGH K9. KB0 M0S NAPCQ PHGZM PHGZT PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM |
DOI | 10.3892/etm.2020.8761 |
DatabaseName | CrossRef ProQuest Central (Corporate) ProQuest Nursing and Allied Health Journals - PSU access expires 11/30/25. Health & Medical Collection ProQuest Central (purchase pre-March 2016) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland British Nursing Database ProQuest Central ProQuest One Community College Proquest Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Health & Medical Collection Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic (New) ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) British Nursing Index with Full Text ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central Nursing & Allied Health Premium ProQuest Health & Medical Complete Health Research Premium Collection ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest Nursing & Allied Health Source (Alumni) ProQuest Central (New) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic ProQuest One Academic Middle East (New) |
Database_xml | – sequence: 1 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1792-1015 |
EndPage | 761 |
ExternalDocumentID | PMC7388387 10_3892_etm_2020_8761 |
GeographicLocations | China |
GeographicLocations_xml | – name: China |
GroupedDBID | --- 0R~ 53G 7RV 7X7 8FI 8FJ AAKDD AAYXX ABDBF ABJNI ABUWG ACGFS ACUHS ADBBV AENEX AFKRA AHMBA ALIPV ALMA_UNASSIGNED_HOLDINGS AN0 BENPR BKEYQ BNQBC BPHCQ BVXVI C45 CCPQU CITATION EBD EBS EJD ESX F5P FYUFA HMCUK HUR HZ~ IAO IHR IPNFZ ITC NAPCQ O9- OVD PHGZM PHGZT PQQKQ PROAC RIG RPM TEORI UKHRP 3V. 7XB 8FK K9. PKEHL PPXIY PQEST PQUKI PRINS 7X8 5PM |
ID | FETCH-LOGICAL-c322t-812873e7d004bbc83e23ac3a8bee05204090b6266875d178d08b59fd19e7b7013 |
IEDL.DBID | 7X7 |
ISSN | 1792-0981 |
IngestDate | Thu Aug 21 14:10:06 EDT 2025 Thu Jul 10 23:31:45 EDT 2025 Sun Jul 13 03:59:42 EDT 2025 Thu Apr 24 23:00:44 EDT 2025 Tue Jul 01 02:59:57 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | false |
IsScholarly | true |
Issue | 2 |
Language | English |
License | This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c322t-812873e7d004bbc83e23ac3a8bee05204090b6266875d178d08b59fd19e7b7013 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 Contributed equally |
OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC7388387 |
PMID | 32742321 |
PQID | 2430606588 |
PQPubID | 2044959 |
PageCount | 8 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_7388387 proquest_miscellaneous_2430094775 proquest_journals_2430606588 crossref_citationtrail_10_3892_etm_2020_8761 crossref_primary_10_3892_etm_2020_8761 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2020-08-01 |
PublicationDateYYYYMMDD | 2020-08-01 |
PublicationDate_xml | – month: 08 year: 2020 text: 2020-08-01 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | Athens |
PublicationPlace_xml | – name: Athens |
PublicationTitle | Experimental and therapeutic medicine |
PublicationYear | 2020 |
Publisher | Spandidos Publications UK Ltd D.A. Spandidos |
Publisher_xml | – name: Spandidos Publications UK Ltd – name: D.A. Spandidos |
SSID | ssj0000561885 |
Score | 2.218454 |
Snippet | The aim of the present study was to determine the association between serum 14-3-3η expression levels and disease risk, inflammation level and disease duration... |
SourceID | pubmedcentral proquest crossref |
SourceType | Open Access Repository Aggregation Database Enrichment Source Index Database |
StartPage | 754 |
SubjectTerms | Age Biomarkers Disease Immunology Patients Proteins Rheumatoid arthritis Rheumatology Signal transduction Statistical analysis |
Title | Serum levels of 14‑3‑3η are associated with increased disease risk, activity and duration of rheumatoid arthritis in Chinese patients |
URI | https://www.proquest.com/docview/2430606588 https://www.proquest.com/docview/2430094775 https://pubmed.ncbi.nlm.nih.gov/PMC7388387 |
Volume | 20 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3NTtwwELYoXHqpoLTqFoqMhPa0Lokdx86pohUIVSpaIZD2FsU_q10JErpJDrwAr8Rb8EzMJN7d7qEcIzt2lBl7vhmPvyHkRKXGSRNLZiPFWTJNBDMytcwCtFZa2Eh0ZTr_XKWXt8nviZyEgFsd0iqXe2K3UbvKYoz8lCcAbtFe6h8PfxlWjcLT1VBC4x3ZQeoyTOlSE7WKsSA61l1VTlA7zqJMxz3NJlhpfuobvInOo--wIcSbZmmNNTczJf8xPRe75EPAjPSsF_Ie2fLlRzIc96TTjyN6s75DVY_okI7XdNSP--QJtoP2nt5hdlBNqymNEyaYeHmmxcLTIojHO4ohWTovEUbW8BiObigmn48o3n_AMhO0KKGp7fUGR1vMfAuot5o7GK-ZdRxJMArFwtweXg_ErfUncntxfvPrkoXqC8zCIm8YWH6thFcOlpExVgvPRWFFoY33mDwDjmFkwB1KweNxsdIu0kZmUxdnXhkFyPIz2S6r0n8hNJHcS7CULsrwYFib1GWaF1byxIJ28AEZLX9-bgM1OVbIuMvBRUFZ5SCrHGWVo6wGZLjq_tBzcvyv4-FSknlYmnW-VqQBOV41w6LCk5Ki9FXb9wG_Vyk5IGpDA1YTIi33Zks5n3X03EpoLbT6-vbkB-Q9fmefS3hItptF678BvmnMUafER2Tn5_nV-PoVxU39hg |
linkProvider | ProQuest |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEF6V9AAXVF4iUGCRIKcstXdt7_qAEI9WKW2jCKVSb8b7iBKp2G1sC-UP8HO48i_4Tcz4kZAD3HqMdrOOMp9nvtmd_YaQVzLSNtR-yIwnOQtmgWA6jAwzQK2lEsYTdZvOs3E0Og8-X4QXO-RndxcGyyo7n1g7apsb3CM_4AGQW4yX6t3VNcOuUXi62rXQaGBx4lbfIWUr3h5_Avu-5vzocPpxxNquAswAeEsGEU1J4aQFeGhtlHBcpEakSjuHRSGQ8HgaaH4ETN76UllP6TCeWT92UktgTLDuLbIbCEhlemT3w-F48mW9q4N8XNV9QAHonHmx8hthT-AF_MCVePede2_ABfnbgXDDbrdrM_8Kdkd75G7LUun7Blb3yI7L7pPBpJG5Xg3pdHNrqxjSAZ1sBLBXD8gPcEDVN3qJ9UgFzWfUD5hg4vcvmi4dTVtAOEtxE5guMiSuBXxsD4solrsPKd64wMYWNM1gqGqQiqst564Cnp0vLKxXzmtVJliFYitwB19vpWKLh-T8RizziPSyPHOPCQ1C7kKIzdaL8Sha6cjGiqcm5IEBPPI-GXZ_fmJaMXTsyXGZQFKEtkrAVgnaKkFb9clgPf2qUQH518T9zpJJ6wyKZAPdPnm5HobXGM9m0szlVTMHMm0pwz6RWwhYPxCFwLdHssW8FgSXQimh5JP_P_wFuT2anp0mp8fjk6fkDv7mppJxn_TKZeWeAbsq9fMW0pR8vem36A9tVThu |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3NjtMwELaWRUJcEL-isICRoKeaJnYcOweEEEu1y8Kqh12ptxD_VK20myxNItQX4JWQeAieiZn8tPQAtz1Gdp2o83nmsz3-hpBXKjZOmlAyGyjOonkkmJGxZRaotdLCBqIp0_nlND46jz7N5GyP_OrvwmBaZe8TG0ftCot75GMeAbnFeKnH8y4tYno4eXf1jWEFKTxp7ctptBA58evvsHwr3x4fgq1fcz75ePbhiHUVBpgFIFcMoptWwisHUDHGauG5yKzItPEeE0Rg8RMYoPwxsHoXKu0CbWQyd2HilVHAnmDcG-SmEjLEOaZmarO_g8xcNxVBAfKcBYkOW4lPYAh87Cu8Bc-DN-CMwt2QuOW5u1maf4W9yV1yp-Or9H0LsHtkz-f3yXDaCl6vR_Rse3-rHNEhnW6lsNcPyA9wRfUlvcDMpJIWcxpGTDDx-yfNVp5mHTS8o7gdTJc5UtgSHrtjI4qJ7yOKdy-wxAXNcmiqW8ziaKuFr4FxF0sH41WLRp8JRqFYFNzDzzvR2PIhOb8Wuzwi-3mR-8eERpJ7CVHaBQkeSmsTu0TzzEoeWUAmH5BR_-entpNFx-ocFyksj9BWKdgqRVulaKsBGW66X7V6IP_qeNBbMu3cQpluQTwgLzfNMKHxlCbLfVG3fWDNrZQcELWDgM0LURJ8tyVfLhppcCW0Flo9-f_LX5BbMHfSz8enJ0_JbfzkNqXxgOxXq9o_A5pVmecNnin5et0T6A94hDs- |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Serum+levels+of+14-3-3%CE%B7+are+associated+with+increased+disease+risk%2C+activity+and+duration+of+rheumatoid+arthritis+in+Chinese+patients&rft.jtitle=Experimental+and+therapeutic+medicine&rft.au=Tu%2C+Jianxin&rft.au=Chen%2C+Xiaowei&rft.au=Dai%2C+Meijie&rft.au=Pan%2C+Axiao&rft.date=2020-08-01&rft.pub=Spandidos+Publications+UK+Ltd&rft.issn=1792-0981&rft.eissn=1792-1015&rft.volume=20&rft.issue=2&rft.spage=754&rft.epage=761&rft_id=info:doi/10.3892%2Fetm.2020.8761&rft.externalDBID=HAS_PDF_LINK |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1792-0981&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1792-0981&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1792-0981&client=summon |